Under CEO Mathai Mammen, Cambridge Biotech Parabilis Medicines Pursues $450 Million IPO
Cancer-focused company could become the eighth Massachusetts biotech to go public in 2026 as the state's biotech IPO market continues to gain momentum
CAMBRIDGE, Mass. — Cambridge-based biotech company Parabilis Medicines has filed plans for an initial public offering that could raise approximately $450 million, according to reporting by the Boston Business Journal.
According to the Boston Business Journal, Parabilis plans to offer 25 million shares priced between $17 and $19 per share. At the midpoint of the proposed range, the IPO would generate approximately $450 million for the company. The shares are expected to trade on the Nasdaq under the ticker symbol “PBLS.”
The company is also receiving additional support from Regeneron Pharmaceuticals, which plans to purchase $75 million worth of shares through a concurrent private placement alongside the IPO, BBJ reported.
The offering includes an option for underwriters — including Leerink Partners, BofA Securities, Evercore ISI, Guggenheim Securities, and LifeSci Capital — to purchase an additional 3.75 million shares.
The planned IPO follows a series of major financing milestones for Parabilis in 2026. Earlier this year, the cancer-focused biotechnology company announced $305 million in new funding and entered into a collaboration agreement with Regeneron. Since its founding, the company has raised more than $800 million from investors including ARCH Venture Partners, Cormorant Asset Management, Fidelity Investments, GV, and RA Capital Management, according to BBJ.
If completed, the offering would make Parabilis the eighth Massachusetts biotechnology company to go public in 2026. Other Massachusetts-based biotech firms that have completed IPOs this year include Seaport Therapeutics, Hemab Therapeutics, Avalyn Pharma, Generate Biomedicines, Aktis Oncology, Kailera Therapeutics, and Odyssey Therapeutics.
The strong pace of biotech IPOs marks a significant improvement from 2025, when only two Massachusetts-linked biotechnology companies went public, BBJ reported.
Parabilis maintains a substantial footprint in Cambridge’s biotechnology ecosystem. The company leases approximately 122,000 square feet of office, laboratory, and manufacturing space at its headquarters in 30 Acorn Park Drive. According to company disclosures cited by BBJ, Parabilis employs 145 full-time staff members and works with an additional 31 full-time consultants.
The planned public offering underscores renewed investor interest in biotechnology companies and reflects the continued strength of the Greater Boston life sciences sector, which remains one of the world’s leading hubs for biotechnology innovation and investment.
